Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and

HILS

Telsey Advisory Group Maintains Outperform on Levi Strauss, Lowers Price Target to $24

By Benzinga Newsdesk

October 7, 5:22 AM

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:LEVI) with a Outperform and lowers the price target from $30 to $24.

LEVI

AI And Industrial Markets To Propel Coherent In Long-Term Recovery, Says Analyst

By Nabaparna Bhattacharya

June 20, 2:03 PM

Needham analyst Jim Ricchiuti reiterated a Buy rating on the shares of Coherent Corp. (NYSE: COHR),

COHR

DA Davidson Downgrades Telos to Neutral

Related Posts

Cathie Wood’s Ark Invest Sells Tesla Following Recent Run-Up: What You Need to Know

Hillstream BioPharma Announces Strategic Reprioritization Of Pipeline To Targeting HER2/HER3 Solid Tumors Via Bispecific And ADC Antibodies And Biologics

Telsey Advisory Group Maintains Outperform on Levi Strauss, Lowers Price Target to $24

AI And Industrial Markets To Propel Coherent In Long-Term Recovery, Says Analyst